The growth of activated human T lymphocytes in response to interleukin-2 (IL-2) is suppressed by transforming growth factor-beta (TGF-beta). This study presents data that show a diminished response of two human lymphoma cell lines to physiologic regulation by TGF-beta. Cell line L-428 was derived from the malignant pleural effusion of a patient with far advanced nodular sclerosing Hodgkin's disease and has been shown to have clonal gene rearrangements characteristic of both B and T lymphocytes. Cell line Mac-1 was derived from the blood of a patient with clinically indolent cutaneous T-cell lymphoma. Both cell lines express the Hodgkin's disease associated antigen, Ki-1. These Ki-1 positive lymphomas are shown to secrete TGF-beta into serum-free culture media. The addition of picogram quantities of exogenous TGF-beta to cell cultures of indolent Ki-1 lymphoma (Mac-1) suppresses IL-2-dependent mitosis; however, the suppression is less than 45%. This suppression correlates with a decrease in the number of IL-2 receptors. No inhibition of Ki-1 positive Hodgkin's cells (L-428) was observed, and proliferation dependent on polyclonal IL-2 was either not affected or was slightly potentiated by TGF-beta. Receptor analysis indicates the absence of IL-2 and TGF-beta receptors on L-428 cells. Thus, these Ki-1 lymphomas derived from activated lymphocytes appear to secrete TGF-beta activity but continue to proliferate because of defective suppression of IL-2 (and related lymphokine)-dependent DNA synthesis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880714 | PMC |
J Clin Exp Hematop
December 2024
Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Intravascular accumulation of atypical large lymphoid cells is a rare condition that necessitates a differential diagnosis of intravascular lymphoma (IVL). Recently, a non-neoplastic condition known as benign atypical intravascular CD30+ T-cell proliferation (BAITP) has been identified. This condition is characterized by CD30+ and CD3+ or CD4+ atypical T-cells and is often associated with trauma and chronic inflammation.
View Article and Find Full Text PDFPurpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.
Patients And Methods: Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy.
Hum Pathol
October 2024
Department of Pathology, School of Basic Medical Sciences and Qilu Hospital, Shandong University, Jinan, China. Electronic address:
Pathol Int
September 2024
Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Lancet Haematol
September 2024
Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Piere Bénite, France; Lymphoma Immuno-Biology Research Unit, Inserm U1111, CIRI, Lyon, France. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!